With 3.9 million shares changed hands, the volume of the stock remained lighter than its average volume of 13.6 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7943 whereas the lowest price it dropped to was $0.713. The 52-week range on LXRX shows that it touched its highest point at $2.45 and its lowest point at $0.28 during that stretch. It currently has a 1-year price target of $2.92. Beta for the stock currently stands at 1.01.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LXRX was up-trending over the past week, with a rise of 19.87%, but this was up by 8.13% over a month. Three-month performance surged to 110.06% while six-month performance rose 8.74%. The stock lost -57.66% in the past year, while it has gained 0.89% so far this year. A look at the trailing 12-month EPS for LXRX yields -0.51 with Next year EPS estimates of -0.31. For the next quarter, that number is -0.07. This implies an EPS growth rate of 49.60% for this year and 2.36% for next year.
Float and Shares Shorts:
At present, 363.18 million LXRX shares are outstanding with a float of 177.07 million shares on hand for trading. On 2025-05-15, short shares totaled 43.03 million, which was 1185.0 higher than short shares on 1744675200. In addition to Dr. Michael S. Exton Ph.D. as the firm’s CEO & Director, Ms. Kristen L. Alexander serves as its Vice President of Finance & Accounting.
Institutional Ownership:
Through their ownership of 0.74926 of LXRX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, LXRX reported revenue of $1262000.0 and operating income of -$25679000.0. The EBITDA in the recently reported quarter was -$23284000.0 and diluted EPS was -$0.07.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LXRX since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With LXRX analysts setting a high price target of 6.0 and a low target of 0.7, the average target price over the next 12 months is 2.58. Based on these targets, LXRX could surge 700.0% to reach the target high and fall by -6.67% to reach the target low. Reaching the average price target will result in a growth of 244.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.58643 being high and -$0.76133 being low. For LXRX, this leads to a yearly average estimate of -$0.67902.
